Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBITDA (2024 - 2025)

Historic EBITDA for Pyxis Oncology (PYXS) over the last 2 years, with Q3 2025 value amounting to -$21.9 million.

  • Pyxis Oncology's EBITDA fell 568.19% to -$21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.4 million, marking a year-over-year change of. This contributed to the annual value of -$77.2 million for FY2024, which is 474.32% down from last year.
  • Latest data reveals that Pyxis Oncology reported EBITDA of -$21.9 million as of Q3 2025, which was down 568.19% from -$18.4 million recorded in Q2 2025.
  • Pyxis Oncology's EBITDA's 5-year high stood at -$3.4 million during Q1 2024, with a 5-year trough of -$35.8 million in Q4 2024.